Clinical Trials

Several completed clinical trials ranging from Phase 2 to Phase 4 have evaluated benzocaine for the management of pain and acute otitis media. Sponsored by both academic medical institutions and pharmaceutical companies, these studies investigated topical anesthesia versus cryoanesthesia for injection pain, as well as otic formulations for otic pain relief.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06165432 Completed
Pain
B.P. Koirala Institute of Health Sciences
 2021-03-19 Phase 4
NCT03116737 Completed
Pain|Acute Otitis Media
Lachlan Pharma Holdings
 2017-01-03 Phase 3
NCT02092454 Completed
Pain|Acute Otitis Media
Otic Therapy LLC
 2013-09 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Benzocaine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Benzocaine reversibly binds to voltage-gated sodium channels on neuronal membranes, inhibiting the inward flux of sodium ions required for membrane depolarization. By blocking the generation and conduction of action potentials along sensory nerve fibers, this compound produces localized analgesia to alleviate pain associated with conditions such as acute otitis media and procedural discomfort.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.